FDA panel weighs first mRNA flu vaccine for those 50 and older

U.S. health advisers are evaluating a novel flu vaccine that employs mRNA technology, the same groundbreaking method used in COVID-19 vaccines. The Food and Drug Administration's advisory committee convened Thursday to consider Moderna's application for its new shot, mFlusvia.

Moderna is seeking approval for mFlusvia as an option for adults aged 50 and above. This marks a significant development in vaccine technology, potentially offering a new approach to influenza prevention that has already demonstrated success against another major respiratory virus.

The advisory committee's deliberations are a key part of the regulatory process. Their recommendation will inform the FDA's final decision on whether to authorize the vaccine for public use. The timing is critical, with the goal of having the vaccine available ahead of the winter flu season.

If approved, mFlusvia would represent the first mRNA-based flu vaccine, signaling a potential shift in how seasonal influenza is managed and prevented, building on the technological advancements made during the COVID-19 pandemic.